Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Humacyte, Inc. (NASDAQ:HUMA) has received an average rating of “Moderate Buy” from the eight brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $6.25.

HUMA has been the topic of a number of recent research reports. TD Cowen dropped their price objective on shares of Humacyte from $1.50 to $1.25 and set a “buy” rating on the stock in a research note on Wednesday, June 17th. HC Wainwright raised their price objective on shares of Humacyte from $3.00 to $4.00 and gave the company a “buy” rating in a research note on Thursday, June 11th. Wall Street Zen raised shares of Humacyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. BTIG Research reaffirmed a “buy” rating and issued a $2.00 price objective on shares of Humacyte in a research note on Tuesday, June 16th. Finally, Benchmark raised their price objective on shares of Humacyte to $2.00 and gave the company a “speculative buy” rating in a research note on Monday, June 1st.

Insider Buying and Selling at Humacyte

In other news, CFO Dale A. Sander sold 45,887 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $0.90, for a total value of $41,298.30. Following the completion of the sale, the chief financial officer owned 267,213 shares in the company, valued at $240,491.70. This represents a 14.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kathleen Sebelius bought 56,818 shares of the stock in a transaction dated Tuesday, May 19th. The stock was purchased at an average price of $0.88 per share, with a total value of $49,999.84. Following the acquisition, the director owned 148,025 shares of the company’s stock, valued at $130,262. The trade was a 62.30% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 3.10% of the company’s stock.

Institutional Trading of Humacyte

Institutional investors and hedge funds have recently made changes to their positions in the company. Prudential Financial Inc. purchased a new position in shares of Humacyte during the second quarter worth approximately $28,000. Financial Advisors Network Inc. purchased a new position in shares of Humacyte during the second quarter worth approximately $28,000. Cerity Partners LLC purchased a new position in shares of Humacyte during the second quarter worth approximately $35,000. Equitable Holdings Inc. purchased a new position in shares of Humacyte during the third quarter worth approximately $29,000. Finally, Imprint Wealth LLC purchased a new position in shares of Humacyte in the third quarter worth $33,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Price Performance

Humacyte stock opened at $0.71 on Monday. The company has a quick ratio of 3.32, a current ratio of 3.93 and a debt-to-equity ratio of 5.46. Humacyte has a 12-month low of $0.55 and a 12-month high of $2.84. The firm’s fifty day moving average is $0.99 and its 200 day moving average is $1.00. The company has a market capitalization of $157.32 million, a PE ratio of -1.24 and a beta of 2.45.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. The firm had revenue of $0.50 million for the quarter, compared to the consensus estimate of $1.46 million. As a group, sell-side analysts predict that Humacyte will post -0.34 EPS for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.